Hong Kong Stock Market Abnormal Movement | BeiGene (06160.HK) Surges Over 6% Again. Application for approval of market release of DLL3/CD3 bispecific antibody tislelizumab accepted.
Zhitong Finance and Economics app learned that BeiGene (06160.HK) has risen by over 6% again, as of press time, rising by 6.28%, to HKD 176.1, with a turnover of HKD 4.26 billion.
Latest
